AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06492798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: umbilical cord mesenchymal stem cell
Description: intravenous infusion of umbilical cord mesenchymal stem cell
Study NCT06492798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cell
Description: intravenous infusion of umbilical cord mesenchymal stem cell
Study NCT05084417 — intervention group
Intervention type: OTHER
Intervention: N/A This is an observational study
Description: As this is an observational study, there are no interventions assigned to either cohort.
Study NCT05908032 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05470114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 is an antibody given by subcutaneous injection.
Study NCT05470114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupixent®
Description: Dupixent® is an antibody given by subcutaneous injection.
Study NCT05873816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProtEmbo - Cerebral Embolic Protection
Description: Subjects will undergo TAVR following placement of the ProtEmbo cerebral embolic protection device.
Study NCT05873816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel - Cerebral Embolic Protection
Description: Subjects will undergo TAVR following placement of the Sentinel cerebral embolic protection device.
Study NCT05965180 — intervention group
Intervention type: DEVICE
Intervention: Fine Needle Photoacoustic Probe
Description: Fine Needle Photoacoustic Probe guided by the standard biopsy system without tissue core extraction
Study NCT05385991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
Description: ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant
Study NCT05323123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Exposure Prophylaxis (PrEP)
Description: FDA-approved oral medication to reduce the risk of HIV infection
Study NCT05323123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis (PrEP)
Description: FDA-approved oral medication to reduce the risk of HIV infection
Study NCT05323123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPARK
Description: SPARK is delivered in a clinic setting by a counselor using motivational interviewing techniques (e.g., open-ended questions, affirmations).
Study NCT05323123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPARK
Description: SPARK is delivered in a clinic setting by a counselor using motivational interviewing techniques (e.g., open-ended questions, affirmations).
Study NCT05323123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthMpowerment
Description: PrEP adherence support app that utilizes engaging social networking and game-based elements, with an in-app portal for individualized live adherence counseling.
Study NCT05725291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-116
Description: Administered intravenously
Study NCT06647797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE Clinical Communication Campaign
Description: * Patient-facing educational materials~* Provider counseling training and job aid
Study NCT06123143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized/structured CPAP weaning protocol
Description: Standardized/structured CPAP weaning protocol up to 32 or 34 weeks gestational age (GA) (based on GA at birth) for infants born at less than 30 weeks GA.
Study NCT06401421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA MRD test
Description: Blood and tissue samples will be collected for the ctDNA MRD test
Study NCT05970822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC3402
Description: Escalating of BC3402 will be administered IV(intravenous)
Study NCT05970822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered daily
Study NCT04922151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 601
Description: intravitreal recombinant humanized anti-VEGF monoclonal antibody
Study NCT04922151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal recombinant humanized anti-VEGF monoclonal antibody
Study NCT05639179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCAR-T Cells
Description: UCAR-T Cellswill be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one:1×10\^6 cells/kg;Dose level two:2×10\^6 cells/kg;Dose level three:5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of UCAR-T Cells at the best dose verified in the first portion.
Study NCT05765279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray 1
Description: HH-120 nasal spray 5 times daily for 3 consecutive days
Study NCT05765279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray 2
Description: HH-120 nasal spray 8 times daily for 3 consecutive days
Study NCT05765279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator 1
Description: Placebo nasal spray 5 times daily for 3 consecutive days
Study NCT05765279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator 2
Description: Placebo nasal spray 8 times daily for 3 consecutive days
Study NCT06141122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A recipe booklet
Description: A recipe resource with visuals in line with the low-residue diet recommendations given to patients before colonoscopy, including cooking instructions for the meals in the diet list.
Study NCT06010693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Participants will receive one Daridorexant 50mg tablet, orally, once daily for about 28 consecutive night on each night approximately 30mintues before participants intends to try to sleep.
Study NCT06010693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive one placebo matched to daridorexant 50 mg tablet , orally, once daily for about 28 consecutive nights on each night approximately 30mintues before participants intends to try to sleep.
Study NCT06066437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A: 177Lu rhPSMA-10.1
Description: Participants will receive 177Lu rhPSMA-10.1 alone.
Study NCT06066437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B: 177Lu rhPSMA-10.1 plus Degarelix
Description: Participants will receive 177Lu rhPSMA-10.1 alone. Participants will receive 177Lu rhPSMA-10.1 with Degarelix
Study NCT06281496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AlloCare
Description: Survivorship supportive care
Study NCT05968768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: Naxitamab will be used only in a hospital setting and must be administered under the supervision of a doctor with experience in the use of oncological therapies. The medicinal product must be administered by a healthcare professional prepared to deal appropriately with severe allergic reactions, including anaphylaxis, in an environment that provides immediate, full access to resuscitation. The patient should have 2 well-functioning IV accesses before any naxitamab treatment is initiated. The solution should be administered through a peripheral or central intravenous catheter. Other concomitant intravenous medicinal products should be administered through separate intravenous access. Before the start of each infusion, premedication will be carried out.
Study NCT04384263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Participants in the Tai Chi group will practice a Yang style, 8-form Tai Chi routine. Specifically, the routine will incorporate slow, deep breathing and mental relaxation by utilizing Tai Chi movements which: 1) are slow and smooth; 2) without break or pause; and 3) have minimal muscular force and exertion. In addition, investigators will emphasize the breathing techniques of Tai Chi exercise. Investigators will adopt methods of progression to enable the participants learn and safely adapt to the Tai Chi routine and improve skills of practicing, specifically: 1) Tai Chi forms will be taught one at a time; 2) participants will receive instructional videos with step-by-step instructions of how to perform the new Tai Chi form that has been taught in the live online Tai Chi exercise session. Participants will be encouraged to practice Tai Chi offline between live online Tai Chi exercise sessions; however, no time requirement will be proposed.
Study NCT05202925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musical Training Program
Description: a weekly 45-minute lesson, one-to-one musical training
Study NCT04968691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation based exercise treatment
Description: The telerehabilitation group will be shown how to do the exercises online by the researcher before each session, 3 sessions a week for 6 weeks, with mobile telecommunication applications, and it will be ensured that the patients do the exercises correctly and are followed up. In addition, at the beginning of each week, videos with the exercise content of that week will also be sent.
Study NCT04968691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home based exercise treatment
Description: n the study, exercise cards were given to the control group and the exercise treatment they were asked to do at home 3 sessions a week for 6 weeks
Study NCT04846088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: A 4mg nicotine pouch product
Study NCT04846088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: A 7mg nicotine pouch product
Study NCT04846088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: A 7mg nicotine pouch product
Study NCT04874662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NAM/B6
Description: Single daily dose administration will take place from Day 0 (V1) to Day 8 (V4) around 8 am after an overnight fast from the subsequent evening at 9 pm.
Study NCT04874662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NAM/B6
Description: Single daily dose administration will take place from Day 0 (V1) to Day 8 (V4) around 8 am after an overnight fast from the subsequent evening at 9 pm.
Study NCT04846088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: A 7mg nicotine pouch product
Study NCT04846088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: A 7mg nicotine pouch product
Study NCT04846088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: A 7mg nicotine pouch product
Study NCT05217641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 MD39.3 mRNA
Description: Administered by IM injection
Study NCT05217641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505 MD39.3 gp151 mRNA
Description: Administered by IM injection
Study NCT04846088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: A 7mg nicotine pouch product
Study NCT04846088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product H
Description: A 7mg nicotine pouch product
Study NCT04951388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(S protein with adjuvant)
Description: Approximately 330 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
Study NCT04951388 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MVC-COV1901(Saline)
Description: Approximately 55 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
Study NCT04846088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product I
Description: A 7mg nicotine pouch product
Study NCT05984537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Participants in the bivalirudin group received a one-time intravenous injection of 0.75 mg/kg during PCI, and then received a continuous intravenous infusion of 1.75 mg/kg/h for 4 hours according to the participants' condition after PCI.
Study NCT05984537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard heparin
Description: Participants in the standard heparin group received a one-time intravenous injection of 50 U/kg of standard heparin during PCI.
Study NCT05262504 — intervention group
Intervention type: DEVICE
Intervention: İntraocular lens implantation
Description: Each participant underwent bilateral sequential cataract surgery and bilateral implantation of a novel non-diffractive EDOF IOL (n=26) or a trifocal IOL (n=26). The interval between the first and second-eye surgeries was 1 to 3 weeks. The patients selected the IOL model after they were fully informed regarding the advantages and disadvantages of each IOL, by their surgeon. Their degree of interest in greater spectacle freedom at far, intermediate, and near distances, as well as their daily activities such as frequency of night driving or reading habits were discussed. The possibility of photic disturbances was described and explained as well.
Study NCT06337006 — intervention group
Intervention type: PROCEDURE
Intervention: Placement of the laryngeal mask airway
Description: Evaluation of patients' chest movement with manual ventilation, airway leak level, airway pressures, fingertip O2 saturation percentage, and capnogram results will be recorded and the correlation between clinical observation and measured parameters will be evaluated.
Study NCT05947214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Decompression Therapy
Description: Group A will be given myofascial decompression therapy.15 minute's moist heat will be given first. Patient was lied prone on couch with their upper torso unclothed, covered with massage oil than placed cup on skin and suction will created by pump. Than drawn over skin along the spine from cervical to thoracic up to lateral border maintain the suction within skin throughout the procedure. The cup massage will conducted for approximately 10 minutes. Patients were informed that the treatment area may become patchy and there are chances of ecchymosis on the same area.
Study NCT06296888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency balloon catheter ablation
Description: Radiofrequency balloon ablation using the HELIOSTAR™ ablation catheter.
Study NCT05947214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positional Release Therapy
Description: Group B will be given Positional Release technique (PRT) after application of moist heat pack for 15 minute. The subjects received PRT will be in supine lying with the therapist sitting on the affected side, tender points were located along with the upper fibers of trapezius muscle. The subject's head was laterally flexed towards the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90 degree and adds slight flexion or extension to fine-tune. The ideal position of comfort achieved was held for a period of 90 sec and followed by passive return of body part to an anatomically neutral position continued for 5 minutes. Treatment duration was 3 sessions per week for 4 weeks.
Study NCT05504070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venclose System (digiRF generator w EVSRF catheter)
Description: The Venclose System is intended for use in endovascular coagulation of blood vessels in patients with superficial vein reflux.
Study NCT05504070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venclose MAVEN System (digiRF generator w MAVEN catheter)
Description: The Venclose MAVEN System is intended for use in endovascular coagulation of blood vessels in patients with perforator or tributary vein reflux.
Study NCT05374395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Support-Delivered Dropout Prevention enhancement
Description: Peer recovery supports will meet with emerging adults for four weekly sessions plus monthly check-ins during the next two months. Peer recovery supports will engage the emerging adults in motivational and skills-based strategies aimed at increasing adherence to services and attendance to treatment sessions.
Study NCT06515418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azelaprag (BGE-105)
Description: Capsules
Study NCT06515418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo for Azelaprag (BGE-105)
Description: Capsules
Study NCT06515418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo for Azelaprag (BGE-105)
Description: Capsules
Study NCT06515418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Subcutaneous Injection
Study NCT06515418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Subcutaneous Injection
Study NCT06515418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide Placebo
Description: Subcutaneous Injection
Study NCT05789199 — intervention group
Intervention type: DRUG
Intervention: Cefiderocol
Description: Cefiderocol is a novel siderophore cephalosporin developed for the treatment of infections caused by Gram-negative bacteria (GNB), including those resistant to carbapenems.
Study NCT05905445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozone gel
Description: the activity of omega-3 in the ozone gel may be advantageous as a host-modulating agent in the supplemental treatment of periodontitis
Study NCT04999514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Parenting, Tuning in to Kids
Description: The Mindful Parenting program consists of 8 weekly 2.5-hour group sessions and 3 weekly individual telephone interview sessions (each lasts for around 15-20 minutes). Program materials are translated into Chinese by local partners of the program developer. The Tuning in to Kids program consists of 8 weekly sessions, each lasting for 2.5 hours. Program materials are translated into Chinese.
Study NCT05711030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block multiple (3) injections
Description: already described in arm description
Study NCT05711030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block single injection
Description: already described in arm description
Study NCT05358210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blueberry Consumption
Description: Participants will consume 1 cup of frozen blueberries daily for the 12 weeks of the intervention. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including other berries, cherries, currants, cabbage, red wine, and eggplant.
Study NCT05358210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dried Date Consumption
Description: Participants will consume 2-3 dried dates daily for the 12 weeks of the intervention, an isocaloric portion of fruit compared to the blueberry group. The study dietitian will provide educational materials and monitor compliance through weekly check-ins. Participants will be instructed to avoid all other high-anthocyanin foods including blueberries, other berries, cherries, currants, cabbage, red wine, and eggplant.
Study NCT02095847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy Imaging
Description: Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the HRME camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera.
Study NCT02095847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine
Description: After hysteroscopy with HRME camera, uterine cavity infused with 10 mL of Proflavine.
Study NCT06166472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK132
Description: IV infusion, specified dose on specified days.
Study NCT05832255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin, 1.5 mg
Description: Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.